Articles

VTB and the EBRD are creating a venture fund with a capital of 3 billion rubles.

Among the initial goals of the fund are investing in information technology and the Internet, semiconductors and biotechnologies, medical and laser equipment, nanotechnology and composite materials, as well as in other promising and profitable areas.

The breakthrough into the future, apparently, is postponed

Biotechnologies in the Russian Federation are practically not developing, stated at the forum the director of the center "Bioengineering" of the Russian Academy of Sciences K.Scriabin. Investing money in the areas listed by him will be in demand in the market and will bring returns. So, the introduction of genetic analysis for artificial insemination in the capital and in St. Petersburg could generate income of up to $ 30 million. "Apparently, there are people who are interested that we do not have this," the well-known scientist noted.

Your health

Biotechnology in Russia: hope is not lost yet

Even under the optimistic scenario, by 2010 Russia will produce only 0.25% of the global volume of biotechnological products. But the authors of the article continue to convince readers that Russia is still capable of not only joining the global biotech race, but also rapidly advancing in the main areas of breakthrough. If everyone votes for United Russia...

Development of biotechnology: Lithuanian scenario

In 2006, a dozen and a half enterprises and institutions signed an agreement on the establishment of the Lithuanian National Biotechnology Platform, which assumed the mission of combining science and production with the prospect of its transformation into an industrial industry.

Physiology and Medicine Award

Nobel Prize laureates in Physiology and Medicine.

Russian medical biotechnologies – current state and development prospects

Transcript of the round table "Russian Medical Biotechnologies – current state and development prospects" organized by the National Information Center for Science and Innovation STRF.Ru .

Development of a regulatory framework for cellular technologies: USA, EU, WHO

Most types of tissue and cell transplantation in the world are going through the initial stage of their formation. Thus, in the USA and the EU, the use of stem cells (with the exception of bone marrow progenitor cells) is limited only to the initial stages of clinical trials involving a small number of patients. In many countries of the world, with the participation of WHO, scientific and expert potential is being concentrated to regulate this kind of activity, regulatory legal acts are being created.

Let's get to work. For the living

Living systems are the second (after nanotechnology) direction, which is actively supported by the state. A lot of money is allocated for the development of this sector of sciences. There are intelligent authors. There are original ideas. Unfortunately, they are not very popular on the market yet.

Chemistry Prize

Nobel Prize winners in Chemistry

Russian fundamental science is trying to help medicine

Scientists of the Academy of Sciences are developing new medicines, diagnostic methods and medical devices in spite of, and not thanks to funding.

Neuroscience and public investment

In 2005, the Department of Neurodynamics and Neurobiology was opened at Nizhny Novgorod State University. When the university received a large grant within the framework of the national project “Education”, an amount equivalent to one million euros was allocated to our department. With this money, we are forming an educational neuroscience laboratory, which will be equipped with modern equipment, which currently has no analogues in Russia.

How Danone Turns Bacteria into Bucks

The main talent of the French is the transformation of bacteria into bucks! They used the most advanced scientific developments to identify microorganisms that contribute to improving a person's well-being and even the freshness of his appearance.

Other life sciences

Biotechnology of Switzerland: no way without small

The biotechnology industry of one of the world's leading pharmaceutical companies – Switzerland – is based on small innovative companies.

Biotechnology on lease

The effectiveness of leasing becomes obvious if the process of obtaining a certain resource is decomposed into components.

Bioethics

Prolonging youth

Aubrey de Grey claims that the average life expectancy of people in developed countries will soon grow to a thousand or more years, and by 2100 to 5000.

New in Gerontology

Laminopathies and the aging process

The problem of genetic control of life expectancy and the aging process has many facets, one of them was highlighted in the study of hereditary diseases included in the group of laminopathies.